Skip to main content

Table 3 Pharmacodynamic (PD) and pharmacokinetic (PK) properties of the ICSs available for the management of asthma in Canada[53, 54]

From: Adrenal suppression: A practical guide to the screening and management of this under-recognized complication of inhaled corticosteroid therapy

ICS Oral bioavailability (%) Lung deposition (%) Particle size (μm) Protein-binding (% not bound) Half-life (h) Systemic clearance (L/h)
Beclomethasone dipropionate 20/40* 50-60 <2.0 13 2.7* 150/120*
Budesonide 11 15-30 >2.5 12 2.0 84
Ciclesonide <1/<1* 50 <2.0 1/1* 0.5/4.8* 152/228*
Fluticasone propionate ≤1 20 2.8 10 14.4 66
  1. *active metabolite